Skip to main content

Starting Out, Already Stars

Premium

Back when we came up with the idea for Tomorrow's PIs — a special issue designed to introduce our readers to a new generation of promising scientists still early in their careers — we really had no clue how the whole thing would pan out. Now, as we're getting ready to send the third annual Tomorrow's PIs edition to the printer, we can't imagine what we'd do without it. People we've profiled in the past have gone on to do great things in science, and no doubt that will continue.

This magazine began in the summer, when we started consulting experts in the systems biology community to get recommendations for scientists who will soon be taking the world by storm. We looked for nominees who are no more than five years or so past their postdoc and then selected a group with a diverse range of scientific interests, backgrounds, and affiliations. After many, many interviews (and more planning meetings than the Genome Technology staff would care to remember), we emerged with the final 30 people who are profiled in this issue. As always, we had far more recommendations than we could actually print, so we'll have mini-profiles of many more young investigators throughout the year at www.genome-technology.com.

We're so grateful to the outstanding cast of scientists who contacted us with nominations — without them, this issue would not be possible.

One thing we noticed this year was a particular challenge in assigning these up-and-coming scientists to technology categories. The research they're engaged in is becoming more integrative, bringing together lots of platforms and concepts from different disciplines. You'll also see that next-gen sequencing is really shaking things up; many of the scientists say that advances in that technology have thoroughly changed the kinds of experiments they're able to do.

The advertisers in this issue have made it possible for us to give a travel stipend to each of the scientists profiled here, so we also thank them very much for their generosity and support of these early-career researchers.

File Attachments
The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.